Results 21 to 30 of about 2,461,363 (302)

The Risk of Perioperative Bleeding in Patients with Dual Antiplatelet Therapy

Український журнал серцево-судинної хірургії, 2021
Background. Patients with dual antiplatelet therapy have high risk of perioperative bleeding. In this article we evaluated the risk of bleeding in patients whose antiplatelet therapy had not been canceled before coronary artery bypass grafting (CABG).
Taras M. Domanskyy, Artur V. Gabriyelyan, Oleg V. Beregovoy, Stanislav I. Filianin, Svitlana S. Moshta   +4 more
doaj   +1 more source

Personalized Antiplatelet Therapy Following Endovascular Revascularization in Peripheral Artery Occlusive Disease: A Novel Concept

EJVES Short Reports, 2015
: Case: A 73 year old patient with a longstanding history of peripheral artery occlusive disease (PAOD) presented with an acute on chronic progression of symptoms, based on a long occlusion of the superficial femoral artery (SFA), which was treated by ...
S.M.O. Peeters Weem, T.C. Leunissen, M. Teraa, E.J. Vonken, G.J. de Borst, F.L. Moll   +5 more
doaj   +1 more source

Type and Duration of Dual Antiplatelet Therapy in Complex Percutaneous Coronary Intervention [PDF]

, 2020
Complex percutaneous coronary intervention (PCI) patients are a high-risk population for ischemic complications. Antiplatelet therapy in such patients remains controversial, as the beneficial effects of more potent agents use or prolonged dual ...
Dimitrios Alexopoulos, Charalampos Varlamos, Despoina-Rafailia Benetou   +2 more
core   +1 more source

Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II trials [PDF]

, 2009
<p><b>Background and Purpose:</b> A number of factors have been associated with postthrombolysis intracerebral hemorrhage, but these have varied across studies.</p> <p><b>Methods:</b> We examined patients with
Demchuk, A., Lees, K.R., Kasner, S.E., Messe, S.R., Cucchiara, B., Levine, S.R., Lyden, P., Sansing, L., Tanne, D.   +8 more
core   +1 more source

Drug resistance with monitored adherence [PDF]

, 2013
Drug resistance can be defined as the failure of a drug to exert its expected effect on pharmacological biomarkers and is caused by pharmacogenetic, cellular or clinical factors.
Walter, Philipp Niklaus
core   +1 more source

Precision antiplatelet therapy

Research and Practice in Thrombosis and Haemostasis, 2023
A State of the Art lecture titled "Personalizing Antiplatelet Therapy Based on Platelet Turnover and Metabolic Phenotype" was presented by Bianca Rocca at the International Society on Thrombosis and Haemostasis (ISTH) Congress in 2022. Increased variability in drug response may be associated with serious, mechanism-based and off-target side effects ...
Rocca, Bianca, Patrono, Carlo
openaire   +2 more sources

Current status and future perspectives of platelet function-guided precision antiplatelet therapy for patients with cerebral infarction. [PDF]

Neuroprotection
Antiplatelet agents target the cyclooxygenase‐1 (COX‐1)/thromboxane A2 (TXA2) and adenosine diphosphate (ADP)‐P2Y12 (cytochrome P450 2C19 [CYP2C19]‐metabolized) platelet activation pathways, resulting in either drug resistance or over‐inhibition. The individualized therapeutic window balances ischemic risk (triggered by high on‐treatment platelet ...
Zhu G, Chen X, Huang X, Tan Q, Cao Q, Yang Y, Lin Y, Yang J.   +7 more
europepmc   +2 more sources

Anti-platelet therapy: ADP receptor antagonists. [PDF]

, 2011
The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis.
Heptinstall, S, Wijeyeratne, YD, Stan Heptinstall, Yanushi Dullewe Wijeyeratne   +3 more
core   +1 more source

Does antithrombotic therapy improve survival with colorectal cancer?

World Journal of Surgical Oncology, 2017
Background The study aimed to evaluate the prognosis for patients with colorectal cancer who underwent surgery while receiving antithrombotic therapy (ATT) across all disease stages and for patients at disease stages 0–III.
Kodai Takahashi, Hideto Ito, Masatoshi Hashimoto, Kazuhito Mita, Hideki Asakawa, Takashi Hayashi, Keiichi Fujino   +6 more
doaj   +1 more source

Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset [PDF]

, 2010
<p><b>Background and Purpose:</b> Antiplatelets (APs) may increase the risk of symptomatic intracerebral hemorrhage (ICH) following intravenous thrombolysis after ischemic stroke.</p> <p><b>Methods:</b> We ...
Wahlgren, N., Luijckx, G-J, Sykora, M., Wahlgren, N,, Diedler, J., Diedler, Jennifer, Overgaard, Karsten, Overgaard, K., Diedler, J, Ringleb, Peter, Uyttenboogaart, M., Ford, G.A., Soinne, Lauri, Overgaard, K, Lees, K.R., Lees, KR, Sykora, M, Uyttenboogaart, M, Uyttenboogaart, Maarten, Ringleb, P., Ahmed, Niaz, Luijckx, G.J., Luijckx, Gert-Jan, Ahmed, N,, Ahmed, N., Lees, Kennedy R., Wahlgren, Nils, Ford, GA, Soinne, L, Soinne, L., Sykora, Marek, Ford, Gary A., Uyttenboogaart, Maarten; id_orcid   +32 more
core   +1 more source